title: New treatment possibilities for opioid-induced bowel dysfunction.
authors: Chair and Department of Palliative Medicine, Poznan University of Medical Sciences, Osiedle Rusa 25 A, 61-245 Poznan, Poland.
authors: Wojciech
authors: W
authors: Leppert
mesh_terms: D003248:Constipation / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008297:Male; D009270:Naloxone / Q000008:administration & dosage*; D009292:Narcotic Antagonists / Q000008:administration & dosage*
chemical_list: D009292:Narcotic Antagonists; D009270:Naloxone
references: Ahmedzai SH, Nauck F, Bar-Sela G, Bosse B, Leyendecker P, Hopp M. A randomized, double-blind, active-controlled, double-dummy, parallel-group study to determine the safety and efficacy of oxycodone/naloxone prolonged-release tablets in patients with moderate/severe, chronic cancer pain. Palliat Med 2012;26:50-60.
references: Bell TJ, Panchal SJ, Miaskowski C, Bolge SC, Milanova T, Williamson R. The prevalence, severity, and impact of opioid-induced bowel dysfunction: results of a US and European patient survey (PROBE 1). Pain Med 2009;10:35-42.
references: Brock C, Olesen SS, Olesen AE, Frøkjaer JB, Andresen T, Drewes AM. Opioid-induced bowel dysfunction. Pathophysiology and management. Drugs 2012;72:1847-1865.
references: Corken A, Green L, Greene P, Avigan M. Methylnaltrexone and gastrointestinal perforation. J Pain Symptom Manage 2010;40:e1-e3.
references: Diego L, Atayee R, Helmons P, Hsiao G, von Gunten CF. Novel opioid antagonists for opioid-induced bowel dysfunction. Expert Opin Investig Drugs 2011;20:1047-1056.
references: Larkin PJ, Sykes NP, Centeno C, Ellershaw JE, Elsner F, Eugene B, Gootjes JRG, Nabal M, Noguera A, Ripamonti C, Zucco F, Zuurmond WWA, on behalf of the European Consensus Group on Constipation in Palliative Care. The management of constipation in palliative care: clinical practice recommendations. Palliat Med 2008;22:796-807.
references: Leppert W. The role of opioid receptor antagonists in the treatment of opioid-induced constipation—a review. Adv Ther 2010;27:714-730.
references: Leppert W. The role of oxycodone/naloxone in chronic pain management. Wspolcz Onkol 2013;17:128-133.
references: Mercadante S, Giarratano A. Combined oral pronged-release oxycodone and naloxone in chronic pain management. Expert Opin Investig Drugs 2013;22:161-166.
references: Rosti G, Gatti A, Costantini A, Sabato AF, Zucco F. Opioid-related bowel dysfunction: prevalence and identification of predictive factors in a large sample of Italian patients on chronic treatment. Eur Rev Med Pharmacol Sci 2010;14:1045-1050.
references: Slatkin N, Thomas J, Lipman AG, Wilson G, Boatwright ML, Wellman C, Zhukovsky DS, Stephenson R, Portenoy R, Stambler N, Israel R. Methylnaltrexone for treatment of opioid-induced constipation in advanced illness patients. J Support Oncol 2009;7:39-46.
references: Webster L, Dhar S, Eldon M, Masuoka L, Lappalainen J, Sostek M. A Phase 2, double-blind, randomized, placebo-controlled, dose-escalation study to evaluate the efficacy, safety, and tolerability of naloxegol in patients with opioid-induced constipation. PAIN® 2013;154:1542-1550.